Cibinqo 50 mg
As listed in the register: Cibinqo 50 mg, filmomhulde tabletten
50 mg · filmomhulde tablet
- Prescription only
- Skin
- Active substance
- Abrocitinib
- Used in
- Skin
- Made by
- Pfizer Europe MA EEIG
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
Mediclarum has not yet retrieved and stored the official label for this product, so none of its text is shown here. Open the official leaflet
How it works
From the US prescribing label for the same active substance (Cibinqo). It describes the substance, not this exact product.
CIBINQO is a Janus kinase (JAK) inhibitor.
Abrocitinib reversibly inhibits JAK1 by blocking the adenosine triphosphate (ATP) binding site.
The metabolism of abrocitinib is mediated by multiple CYP enzymes, CYP2C19 (~53%), CYP2C9 (~30%), CYP3A4 (~11%) and CYP2B6 (~6%).
After a single radiolabeled abrocitinib dose, less than 1% of the dose was excreted in urine as unchanged drug.
Quoted from the prescribing label, sections “Mechanism of Action” and “Pharmacokinetics”. DailyMed · 2026-09-09
Safety of the active substance
From the US prescribing label for the same active substance (Cibinqo). It describes the substance, not this exact product.
WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS, and THROMBOSIS WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS See full prescribing information for complete boxed warning..
- CIBINQO is contraindicated in patients taking antiplatelet therapies, except for low-dose aspirin (≤81 mg daily), during the first 3 months of treatment [see Warnings and Precautions (5.7), Drug Interactions (7.2), and Clinical Pharmacology (12.2) ].
- Antiplatelet therapies except for low-dose aspirin (≤81 mg daily), during the first 3 months of treatment.
Most common adverse events (≥1% with CIBINQO 100 mg) are nasopharyngitis, nausea, headache, herpes simplex, increased blood creatine phosphokinase, dizziness, urinary tract infection, fatigue, acne, vomiting, impetigo, oropharyngeal pain, hypertension, influenza, gastroenteritis, and dermatitis contact.
Quoted from the US prescribing label for the same active substance. Your own pack’s leaflet is the authority for your product. DailyMed
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United States2 matching products
European UnionNo exact match for this strength and form
Spain1 matching products
SwitzerlandNo exact match for this strength and form
Details
| Made by | Pfizer Europe MA EEIG |
|---|---|
| Active substance | Abrocitinib |
| Used in | Skin |
| Strength | 50 mg |
| Form | filmomhulde tablet |
| Classification | D11AH08 · Skin |
| Route | oraal gebruik |
| Dispensing (as stated by the register) | Uitsluitend recept |
| Name in the register | Cibinqo 50 mg, filmomhulde tabletten |
| RVG | EU/1/21/1593 |
Source: Geneesmiddeleninformatiebank · 2026-09-30 · not reviewed by a clinician
Bron: College ter Beoordeling van Geneesmiddelen (CBG). De Rijksoverheid is het niet automatisch eens met de inhoud van deze site. Reuse terms: CC0 1.0 (CBG website).
Same active substance
These contain the same substance. That does not mean one can replace another — ask a pharmacist.